April 01, 2025

A Different Perspective on an Age-Old Disease

Discover how Optical Coherence Tomography (OCT) technology can revolutionize the management of posterior segment diseases in this engaging editorial content by Dr. James L. Fanelli.

Optometric Management

April 01, 2025

Coding Q&A: Coding Guidelines for Wet AMD

Ensure compliance and prompt payment by using proper ICD-10-CM codes for diagnosing patients with exudative age-related macular degeneration (wet AMD). Learn the guidelines for coding specific eye conditions and disease stages.

Retinal Physician

April 01, 2025

Cemiplimab Effective for Advanced cSCC

Meta-analysis of 19 studies reveals promising 54.5% objective response rate and manageable safety profile for PD-1 inhibitor in treating advanced cutaneous squamous cell carcinoma.

Conexiant

March 31, 2025

Tariff Threat: Drugs Could Cost U.S. $750M More

New research reveals 25% tariffs on Canadian pharmaceuticals would impact critical medications, strain supply chains, and potentially increase costs—with 28 drugs having no alternative suppliers.

Conexiant

March 28, 2025

Novel Limonene-Lipid Formulation May Help Alleviate Xerostomia in Patients With Cancer

Researchers examined the combination of a novel lipid formulation and a natural citrus essential oil to determine whether it may relieve xerostomia among patients with cancer.

The ASCO Post

March 25, 2025

Does Bicalutamide Help Hair Loss?

A new randomized clinical trial found no added benefit from combining bicalutamide with minoxidil in the treatment of female pattern hair loss, contrasting with findings from previous retrospective studies and noting that further research on antiandrogen therapy is needed.

Conexiant

March 24, 2025

HS Guidelines for Special Populations

"These guidelines address the unique needs of diverse groups typically underrepresented in clinical trials, and highlight the importance of a multidisciplinary approach."

Conexiant

March 24, 2025

Tildrakizumab Shows Lasting Efficacy in Scalp Psoriasis

Tildrakizumab may provide durable response for scalp psoriasis, a phase 3b study found, confirming sustained efficacy and safety through 52 weeks.

Conexiant

March 21, 2025

Biosimilars Match Adalimumab Originator Efficacy for Psoriasis

Amjevita and Imraldi were as effective as Humira for both new starters and patients switching from Humira, researchers concluded

Conexiant